ARCHIVES

Cancer Groups Endorse Richard Pazdur for Head of FDA’s New Office of Oncology Drug Products. Five Candidates Are In the Running for the Job, Sources Said.

This article is from The Cancer Letter archive.

Vol. 31 No. 07 | February 18, 2005

Download PDF Visit The Full Archive

Related Articles

FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds

December 26, 2003

Taxotere Added To Regimen Improves Survival, Study Finds

July 29, 2005

DCE Concepts Approved

June 27, 1986

ACS Challenged To Clarify Position On FDA Reform

March 1, 1996

DCBD Concepts Approved

November 8, 1985

Talking Back: FDA Faces Challenges Over Avastin & Prostate Cancer Prevention

January 21, 2011